| Schedule of earnings per share, basic and diluted |
| |
| | | |
| | | |
| | |
| | |
Fiscal Year Ended April 30, | |
| | |
2023 | | |
2022 | | |
2021 | |
| Numerator | |
| | |
| | |
| |
| Net income | |
$ | 560 | | |
$ | 127,672 | | |
$ | 11,212 | |
| Series E preferred stock accumulated dividends | |
| – | | |
| – | | |
| (4,455 | ) |
| Impact of Series E preferred stock redemption | |
| – | | |
| – | | |
| (3,439 | ) |
| Net income attributable to common stockholders, basic | |
$ | 560 | | |
$ | 127,672 | | |
$ | 3,318 | |
| Add interest expense on Convertible Notes, net of tax | |
| – | | |
| 1,954 | | |
| – | |
| Net income attributable to common stockholders, diluted | |
$ | 560 | | |
$ | 129,626 | | |
$ | 3,318 | |
| Denominator | |
| | | |
| | | |
| | |
| Weighted average basic common shares outstanding | |
| 62,268 | | |
| 61,484 | | |
| 58,222 | |
| Effect of dilutive securities: | |
| | | |
| | | |
| | |
| Stock options | |
| 1,248 | | |
| 1,830 | | |
| 909 | |
| RSUs, PSUs and ESPP | |
| 266 | | |
| 384 | | |
| 295 | |
| Convertible Notes | |
| – | | |
| 6,776 | | |
| – | |
| Weighted average dilutive common shares outstanding | |
| 63,782 | | |
| 70,474 | | |
| 59,426 | |
| | |
| | | |
| | | |
| | |
| Net income per share attributable to common stockholders: | |
| | | |
| | | |
| | |
| Basic | |
$ | 0.01 | | |
$ | 2.08 | | |
$ | 0.06 | |
| Diluted | |
$ | 0.01 | | |
$ | 1.84 | | |
$ | 0.06 | |
|
| Schedule of antidilutive shares |
| |
| | | |
| | | |
| | |
| | |
Fiscal Year Ended April 30, | |
| | |
2023 | | |
2022 | | |
2021 | |
| Stock options | |
| 46 | | |
| 43 | | |
| 829 | |
| RSUs, PSUs and ESPP | |
| 253 | | |
| 9 | | |
| – | |
| Convertible Notes | |
| 6,776 | | |
| – | | |
| 928 | |
| Series E Preferred Stock | |
| – | | |
| – | | |
| 1,864 | |
| Total | |
| 7,075 | | |
| 52 | | |
| 3,621 | |
|